Welcome to Eloquest Healthcare!

About Our Company

Eloquest Healthcare Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their clinicians, and patients. We collaborate with our customers to deliver safer, more compassionate care.

Eloquest Healthcare’s products support strategies that prevent hospital acquired infections and provide better outcomes, higher quality and lower healthcare costs.

Our Products

Why Partner With Us?

null
null

Better Clinical Outcomes

Reduced risk of central line-associated bloodstream infections (CLABSI), post-op wound contamination, and skin injuries.
null
null

Higher Quality Support

Educational resources, knowledgeable field representatives, home office support.
null
null

Lower Cost of Care

Reduced material cost from waste and lower payment penalties from improvement in care quality.

3 Main Reasons to Choose Eloquest

Better Clinical Outcomes

We strive for better clinical outcomes. Eloquest Healthcare works towards reduced risk of central line-associated bloodstream infections (CLABSI), post-op wound contamination, and skin injuries.

Higher Quality Support

You’re not alone. Eloquest Healthcare takes pride in providing higher quality support to you and your facility. Educational resources, knowledgeable field representatives, home office support are just a few of the things we provide for you.

Lower Cost of Care

Eloquest Healthcare aims to lower your facility’s cost of care through reduced material cost from waste and lower payment penalties from improvement in care quality.

RECENT NEWS & EVENTS

august, 2018

No Events

ReliaTect® and Post-Op Risk Prevention

This 3-part series has reviewed the financial impact of SSIs  and emerging trends in SSI prevention. It is well accepted that hospital-acquired infection (HAI) after surgery or insertion of a device increases morbidity, mortality, and costs of care for patients and hospitals. Emerging trends in SSI prevention include antimicrobial dressings, with the purpose of protecting…

Read more

Financial Impact of Surgical Site Infections (SSIs)

Welcome to a new 3-part series focusing on SSIs. SSIs are the most common type of hospital-acquired infection (HAI). They occur an estimated 160,000 to 300,000 times per year and account for more than 20% of all HAIs.1 And while the negative clinical outcomes associated with SSIs (ie, morbidity and mortality) are commonly known, there…

Read more